Watch for longer-term follow-up data from the phase Ib portion and interim results from the global phase III EMBOLD SCLC-301 trial, which will determine registrational potential. The 61% ORR is encouraging but based on a small sample; durability data and overall survival readouts are needed to confirm commercial viability.
Price Chart
Executive Summary
GSK announced first global phase Ib data for its B7-H3-targeted ADC, Ris-Rez, in relapsed extensive-stage small cell lung cancer (ES-SCLC), showing a 61% confirmed objective response rate at the 8 mg/kg dose. The data support dose selection for the ongoing global phase III EMBOLD SCLC-301 trial and build on prior positive Chinese phase III results. This is an early-stage readout with a small sample (n=18 evaluable at 8 mg/kg), and the filing contains no financial figures or revenue impact.
Key Facts
- 61% confirmed objective response rate (ORR) at 8 mg/kg dose in phase Ib (n=11/18; 95% CI: 35.7-82.7)
- 32% ORR at 6 mg/kg dose (n=7/22; 95% CI: 13.9-54.9)
- Grade 3+ treatment-related adverse events: 42% at 8 mg/kg, 15% at 6 mg/kg
- Interstitial lung disease rate low at 2% (1/50 patients, grade 2)
- Data presented at ESMO 2026; supports ongoing global phase III EMBOLD SCLC-301 trial
- Ris-Rez has Breakthrough Therapy Designation in US and PRIME designation in EU for relapsed/refractory ES-SCLC
Financial Impact
No financial figures provided in filing; early clinical data with no revenue or cost disclosure
Risk Factors
- Small sample size (n=18 evaluable at 8 mg/kg) limits statistical reliability
- Grade 3+ TRAE rate of 42% at 8 mg/kg may raise tolerability concerns in broader population
- Phase III failure risk remains; prior GSK pipeline setbacks (e.g., Blenrep) highlight ADC development risk
- No financial data or revenue projections in filing; commercial impact uncertain
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-009023 |
| Document: 0001654954-26-009023-index-headers.html | 0001654954-26-009023 |
| Document: 0001654954-26-009023-index.html | 0001654954-26-009023 |
| Document: 0001654954-26-009023.txt | 0001654954-26-009023 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $50.94 (−0.31%) |
Oct 26, 2026 1d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $50.94 (−0.31%) |
Oct 26, 2026 1d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $50.94 (−0.31%) |
Oct 26, 2026 1d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $50.94 (−0.31%) |
Oct 21, 2026 6d ago | 6-K | $50.02 | awaiting T+5 | awaiting T+5 | $50.94 (+1.84%) |
Oct 19, 2026 8d ago | 6-K | $49.46 $51.10 | ▲ +3.32% | ▲ +3.46% | $50.94 (+2.99%) |
Oct 19, 2026 8d ago | 6-K | $49.46 $51.10 | ▲ +3.32% | ▲ +3.46% | $50.94 (+2.99%) |
Oct 15, 2026 12d ago | 6-K | $49.02 $51.21 | ▲ +4.47% | ▲ +5.48% | $50.94 (+3.92%) |
Oct 14, 2026 13d ago | 6-K | $47.87 $50.02 | ▲ +4.49% | ▲ +4.04% | $50.94 (+6.41%) |
Oct 13, 2026 14d ago | 6-K | $46.27 $50.63 | ▲ +9.42% | ▲ +10.57% | $50.94 (+10.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers